BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. 1991

T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
First Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

The pharmacokinetics of a new Class I antiarrhythmic agent, SUN 1165, has been studied in 32 patients with varying degrees of renal impairment following a single oral dose of 50 mg. The apparent volume of distribution at steady state was 1.48 l.kg-1, the absorption rate constant was 2.2 h-1, and plasma protein binding was 26.8% in subjects with normal renal function. These variables were not altered with renal impairment. More than 60% of SUN 1165 given orally was excreted unchanged via the kidney, both by tubular secretion and glomerular filtration. The elimination rate constant, the apparent total body clearance and the apparent renal clearance were linearly correlated with the endogenous creatinine clearance. The half-time of elimination was 3.4 h in normal subjects and it was prolonged to 23.7 h in severe renal failure (creatinine clearance below 20 ml.min-1.1.48 m-2). Dosage adjustment of SUN 1165 is necessary in renal failure.

UI MeSH Term Description Entries
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Electrophysiological actions of N-(2,6-dimethylphenyl)-8-pyrrolizidine-acetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent.
January 1986, Journal of cardiovascular pharmacology,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction.
January 1985, Arzneimittel-Forschung,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent.
January 1985, Arzneimittel-Forschung,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Mechanism of inhibition by SUN 1165, a new Na channel blocking antiarrhythmic agent, of cardiac glycoside-induced triggered activity.
January 1988, European journal of pharmacology,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig.
January 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.
January 1978, Clinical pharmacokinetics,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles.
April 1988, Journal of cardiovascular pharmacology,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics.
February 1982, Circulation,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Effects of a new antiarrhythmic compound SUN 1165 [N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride] on the sodium currents in isolated single rat ventricular cells.
June 1984, Naunyn-Schmiedeberg's archives of pharmacology,
T Takabatake, and H Ohta, and Y Yamamoto, and Y Ishida, and H Hara, and Y Ushiogi, and S Nakamura, and N Hashimoto, and T Sasaki, and S Satoh
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics.
April 1992, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!